Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Post-Exposure Prophylaxis for Covid-19: A Systematic Review Publisher Pubmed



Seyedalinaghi S1 ; Karimi A2 ; Pashaei Z1 ; Shobeiri P2 ; Janfaza N3 ; Behnezhad F4 ; Ghasemzadeh A5 ; Barzegary A6 ; Arjmand G7 ; Noroozi A6 ; Shojaei A1 ; Amiri A1 ; Vahedi F2 ; Mahalleh M2 Show All Authors
Authors
  1. Seyedalinaghi S1
  2. Karimi A2
  3. Pashaei Z1
  4. Shobeiri P2
  5. Janfaza N3
  6. Behnezhad F4
  7. Ghasemzadeh A5
  8. Barzegary A6
  9. Arjmand G7
  10. Noroozi A6
  11. Shojaei A1
  12. Amiri A1
  13. Vahedi F2
  14. Mahalleh M2
  15. Shamsabadi A8
  16. Dashti M5
  17. Afsahi AM9
  18. Mehraeen E10
  19. Dadras O1, 11
Show Affiliations
Authors Affiliations
  1. 1. Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Internal Medicine Department, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Radiology, Tabriz University of Medical Sciences, Tabriz, Iran
  6. 6. School of Medicine, Islamic Azad University, Tehran, Iran
  7. 7. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Department of Health Information Technology, Esfarayen Faculty of Medical Sciences, Esfarayen, Iran
  9. 9. Department of Radiology, School of Medicine, University of California, San Diego (UCSD), CA, United States
  10. 10. Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran
  11. 11. Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

Source: Infectious Disorders - Drug Targets Published:2023


Abstract

Introduction: SARS-CoV-2 cause pneumonia can spread across the lung and lead to acute respiratory distress syndrome (ARDS) in severe cases. Post-exposure prophylaxis has shown great potential to prevent the transmission of some viral infections; however, such results for COVID-19 are still inconclusive. Methods: Therefore, the aim of this study was to systematically review the resources that utilized post-exposure prophylaxis (PEP) for COVID-19 and the possible clinical benefits of such drugs. An orga-nized search of relevant literature was done using the keywords and search queries on public databases of Cochrane, PubMed, Web of Science and Scopus from December 2019 to August 23, 2021. Original resources that had the inclusion criteria were included after two-phase title/abstract and full-text screenings. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Results: Out of 841 retrieved records 17 resources were appropriate to include in the systematic re-view. Hydroxychloroquine with a daily dose of 400-800 mg and a duration of 5-14 days was the most frequently used agent for PEP. Chloroquine was recommended to use to control treatment in patients with mild to severe COVID-19 pneumonia. Other agents like Lopinavir-ritonavir (LPV/r), angiotensin-converting enzyme inhibitors (ACEIs), Angiotensin receptor blockers (ARBs), Vitamin D, arbidol, thymosin drugs, and Xin guan no.1 (XG.1, a Chinese formula medicine) have also been applied in some studies. Conclusion: Current evidence demonstrated no established clinical benefits of any drug as PEP in individuals with COVID-19. However, scarce indication occurs for the beneficial effects of some agents, but more studies are needed to explore such effects. © 2023 Bentham Science Publishers.
Related Docs
View other Related Docs
1. Can Anti-Parasitic Drugs Help Control Covid-19?, Future Virology (2022)
2. Classification of the Present Pharmaceutical Agents Based on the Possible Effective Mechanism on the Covid-19 Infection, DARU# Journal of Pharmaceutical Sciences (2020)
3. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)
4. An Overview on the Treatments and Prevention Against Covid-19, Virology Journal (2023)
5. Current Treatments and Therapeutic Options for Covid-19 Patients: A Systematic Review, Infectious Disorders - Drug Targets (2022)
6. Recent Findings on the Coronavirus Disease 2019 (Covid-19); Immunopathogenesis and Immunotherapeutics, International Immunopharmacology (2020)
7. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)
8. Covid-19 in Patients With Hypertension, Advances in Experimental Medicine and Biology (2021)
Experts (# of related papers)
View all Related Experts
Seyed Ahmad Seyed Alinaghi (13)
Nima Rezaei (12)
Other Related Docs
9. Covid-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods, Anti-Cancer Agents in Medicinal Chemistry (2021)
10. The Situation of Small Molecules Targeting Key Proteins in Combatting Sars-Cov-2: Synthesis, Metabolic Pathway, Mechanism of Action, and Potential Therapeutic Applications, Mini-Reviews in Medicinal Chemistry (2022)
11. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)
12. Effects of Angiotensin Receptor Blockers (Arbs) on In-Hospital Outcomes of Patients With Hypertension and Confirmed or Clinically Suspected Covid-19, American Journal of Hypertension (2020)
13. Sars-Cov-2: From the Pathogenesis to Potential Anti-Viral Treatments, Biomedicine and Pharmacotherapy (2021)
14. The Prophylaxis and Treatment Potential of Supplements for Covid-19, European Journal of Pharmacology (2020)
15. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (Covid-19), Journal of Cardiovascular Pharmacology (2020)
16. Covid-19: A Review on Treatment Strategies and Candidate Vaccines, Scientific Journal of Kurdistan University of Medical Sciences (2021)
17. The Emerging Role of Micrornas in the Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Infection, International Immunopharmacology (2021)
18. Efficacy and Safety of Arbidol (Umifenovir) in Patients With Covid-19: A Systematic Review and Meta-Analysis, Immunity# Inflammation and Disease (2021)
19. Effect the Pre-Exposure Prophylactic of Hydroxychloroquine on Severe Covid-19 Disease: A Randomized Controlled Trial; [Влияние Доконтактной Профилактики Гидроксихлорохином На Развитие Тяжелого Covid-19: Рандомизированное Контролируемое Исследование], Russian Journal of Infection and Immunity (2023)
20. Effect of Covid-19 Medications on Corrected Qt Interval and Induction of Torsade De Pointes: Results of a Multicenter National Survey, International Journal of Clinical Practice (2021)
21. The Use of Mesenchymal Stem Cells in the Process of Treatment and Tissue Regeneration After Recovery in Patients With Covid-19, Gene (2021)
22. Corona Virus Disease 2019 (Covid-19) As a System-Level Infectious Disease With Distinct Sex Disparities, Frontiers in Immunology (2021)
23. Covid-19: A Systematic Review and Update on Prevention, Diagnosis, and Treatment, MedComm (2022)
24. Remdesivir: A Beacon of Hope From Ebola Virus Disease to Covid-19, Reviews in Medical Virology (2020)
25. Nanomedicine “New Food for an Old Mouth”: Novel Approaches for the Treatment of Covid-19, Drug Delivery Letters (2023)
26. A Rapid Strategy for Repurposing Drugs for Covid-19, Pharmaceutical Sciences (2020)
27. Cardiovascular Complications of Covid-19: Pharmacotherapy Perspective, Cardiovascular Drugs and Therapy (2021)
28. Covid-19: Transmission, Prevention, and Potential Therapeutic Opportunities, Clinica Chimica Acta (2020)
29. Existing Antiviral Options Against Sars-Cov-2 Replication in Covid-19 Patients, Future Microbiology (2020)
30. Lopinavir/Ritonavir for Covid-19: A Systematic Review and Meta-Analysis, Journal of Pharmacy and Pharmaceutical Sciences (2021)
31. Estimating the Size of the Hidden Population of Covid-19, Infectious Disorders - Drug Targets (2024)
32. Coronavirus Disease 2019 (Covid-19) in Pediatric Patients With Autoimmune Disorders, European Journal of Pediatrics (2023)
33. Prevalence of Covid-19-Like Symptoms Among People Living With Hiv, and Using Antiretroviral Therapy for Prevention and Treatment, Current HIV Research (2020)
34. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm, Journal of Clinical Immunology (2020)
35. The Effectiveness of Face Masks in Preventing Covid-19 Transmission: A Systematic Review, Infectious Disorders - Drug Targets (2023)
36. Technology in the Era of Covid-19: A Systematic Review of Current Evidence, Infectious Disorders - Drug Targets (2022)
37. Impact of Sars-Cov-2 Pandemic on Patients With Primary Immunodeficiency, Journal of Clinical Immunology (2021)
38. Comparison of the Eight Different Treatment Regimens for the Hospitalized Patients With Covid-19: A Retrospective Cohort Study, Journal of Cellular and Molecular Anesthesia (2021)
39. Association Between Cardiometabolic Risk Factors and Covid-19 Susceptibility, Severity and Mortality: A Review, Journal of Diabetes and Metabolic Disorders (2021)
40. Genetic Susceptibility of Covid-19: A Systematic Review of Current Evidence, European Journal of Medical Research (2021)
41. Antiretrovirals for Prophylaxis Against Covid-19: A Comprehensive Literature Review, Journal of Clinical Pharmacology (2021)
42. The Role of Autophagy in Controlling Sars-Cov-2 Infection: An Overview on Virophagy-Mediated Molecular Drug Targets, Cell Biology International (2021)
43. Recent Advances in Antibody-Based Immunotherapy Strategies for Covid-19, Journal of Cellular Biochemistry (2021)
44. State-Of-The-Art of Nanodiagnostics and Nanotherapeutics Against Sars-Cov-2, ACS Applied Materials and Interfaces (2021)
45. Association of Vitamin D Receptor Gene Polymorphisms and Clinical/Severe Outcomes of Covid-19 Patients, Infection# Genetics and Evolution (2021)
46. Therapeutic and Diagnostic Applications of Nanoparticles in the Management of Covid-19: A Comprehensive Overview, Virology Journal (2022)
47. Prophylaxis With Chloroquine and Hydroxychloroquine in Covid-19, Journal of Iranian Medical Council (2020)
48. Real Clinical Practice and Therapeutic Management Following Covid-19 Crisis in Two Hospitals in Iran: A Statistical and Conceptual View, Tanaffos (2020)
49. Antiviral Optical Techniques As a Possible Novel Approach to Covid-19 Treatment, Journal of Innovative Optical Health Sciences (2021)
50. Immunopathological Similarities Between Covid-19 and Influenza: Investigating the Consequences of Co-Infection, Microbial Pathogenesis (2021)